At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 87 enrolled
Drug / intervention
LAS100977 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Strengths of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating LAS100977, Reference, and 1 other intervention for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 87 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the pharmacodynamics (bronchodilation) of single doses of inhaled LAS100977 in COPD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedAug 30, 2011
Enrollment StartAug 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 14.8 years ago
Interventions
LAS100977drug
Dry powder inhalation,Once daily, single dose
LAS100977drug
Dry powder inhalation,Once daily, single dose
LAS100977drug
Dry powder inhalation,Once daily, single dose
LAS100977drug
Dry powder inhalation,Once daily, single dose
Referencedrug
Dry powder inhalation (capsule),single dose
Placebodrug
Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose